A NEW skin cancer risk stratification tool for solid organ transplant recipients shows strong international validation but inconsistent clinical adoption across transplant care settings. The Skin and Ultraviolet Neoplasia Risk Assessment Calculator (SUNTRAC) has emerged as the most current and rigorously tested model for identifying which patients are most likely to develop skin cancer following transplantation, yet a gap between the evidence base and routine clinical practice continues to limit its impact.
Skin Cancer Risk in Solid Organ Transplant Recipients
Skin cancer is the most common malignancy in solid organ transplant recipients (SOTRs), driven largely by the immunosuppressive regimens required to prevent graft rejection. Long-term immunosuppression compromises the immune system’s ability to identify and eliminate transformed cells, creating a permissive environment for cutaneous malignancy. The risk is not uniform across this population, however, and is shaped by a range of patient-specific factors that vary considerably in clinical significance.
SUNTRAC stratifies skin cancer risk using five key variables: Caucasian ethnicity, a prior history of skin cancer, older age at the time of transplant, male sex, and thoracic organ transplantation. Each factor carries a weighted point value, placing patients into one of four risk tiers including low, medium, high, or very high, with corresponding screening recommendations tailored to each category. The five-year cumulative incidence of skin cancer ranges from approximately 1% in the lowest-risk group to nearly 45% in the highest, underscoring the clinical utility of stratification over a one-size-fits-all surveillance approach.
International Validation and Expanded Utility
Large European validation studies have confirmed that SUNTRAC performs reliably across diverse SOTR populations, with observed skin cancer incidences closely matching tool predictions across risk groups. Crucially, this validation extended SUNTRAC’s utility beyond squamous cell carcinoma, its original focus, to include basal cell carcinoma, broadening the scope of the tool’s clinical relevance. Additional research has explored refinements to improve accuracy, including work addressing personalization for patients who fall outside the original study demographics.
Despite robust external validation and wide availability, SUNTRAC remains inconsistently integrated into transplant referral pathways and guideline-driven care. Standardized protocols for its clinical implementation are lacking at both national and international levels, and the tool is not uniformly embedded in transplant center workflows. The authors highlight this as a persistent gap between evidence and routine practice, one with direct implications for early detection and preventive care in a population already at elevated oncologic risk. Future priorities include greater personalization of the tool, incorporation of additional risk factors, and clearer institutional protocols to support integration into standard post-transplant follow-up.
Reference
Al Bouzidi W et al. Skin cancer screening in solid organ transplant recipients: development of the SUNTRAC tool. Curr Opin Oncol. 2026;38(2):102–106.
Featured Image: Evgeniy Kalinovskiy on Adobe Stock.
